Bruker Corporation announced on October 17, 2024, that the European Unified Patent Court (UPC) ruled in favor of its NanoString business. The ruling invalidated European Patent No. 2794928B1, which 10x Genomics had asserted against NanoString’s CosMx® Spatial Molecular Imager (SMI) products in Europe.
This decision follows a May 2024 ruling by the German Federal Patent Court, which also declared the 928 Patent invalid and revoked it. The consistent invalidation of the patent in European courts is a significant legal victory for Bruker.
The favorable outcome removes a legal challenge against a key product line within Bruker's spatial biology portfolio. This allows Bruker's NanoString business to continue offering its CosMx SMI products in Europe without this specific patent infringement concern.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.